E-MAIL ( preferred):



PHONE ( preferred):



## Quote Request ANTIBODY PROJECT

## Date: PRINCIPAL INVESTIGATOR: TITLE: INSTITUTION: ADDRESS:

FAX (□preferred):

To ensure that we understand your needs and project requirements, please fill out or type in this form. When information is not available to you or cannot be disclosed, skip the question leaving it blank. FAX us the completed form to 203-653-2251. Please make sure that, if necessary, confidential disclosure agreement is executed before submitting this form.

CELL ( preferred):

|   |                                   |              |  | ANTIBODY                |            |  |  |
|---|-----------------------------------|--------------|--|-------------------------|------------|--|--|
| ANTIBODY NAME:                          |                                   |              | Polyclonal antibody Monoclonal antibody. |                         | ISOTYPE:   |  |  |
| IMMUNOGEN: SP                           |                                   | SPECIFICITY  | /ANTIGEN:                                | SPECIES:                | RAISED IN: |  |  |
| Ful                                     | l length                          | ☐ (F         | $[ab)_2$ $\square$ I                     | Fab                     |            |  |  |
| REFERE                                  | NCE SAMPLE                        | AVAILABILIT  | Y:                                       |                         |            |  |  |
|   | Antibody Specify:                 |              |  |                         |            |  |  |
|   | Antigen Specify:                  |              |  |                         |            |  |  |
| ANTIBO                                  | DY SOURCE:                        |              |  |                         |            |  |  |
|   | Ascites flu                       | id Descri    | be:                                      |                         |            |  |  |
|   | Estimated antibody concentration: |              |  |                         |            |  |  |
| Hybridoma Describe:                     |                                   |              |  |                         |            |  |  |
|   | Expression:                       |              |  |                         |            |  |  |
|   |                                   | Growtl       | Growth condtions:                        |                         |            |  |  |
| PURIFIC                                 | ATION PROTO                       | OCOLS (paste | references and                           | l/or your own protocols | ):         |  |  |
|   |                                   | (1           |  | J                       | ,          |  |  |
|   |                                   |              |  |                         |            |  |  |
|   |                                   |              |  |                         |            |  |  |
|   |                                   |              |  | QUESTED SERVICES        |            |  |  |
| ∐ Cel                                   | l growth co                       | nditions opt | timization. Spe                          | ecify:                  |            |  |  |
| Conditioned media production. Scale, L: |                                   |              |  |                         |            |  |  |





| Antibody purification:   |   |   |                |          |  |  |  |  |  |
|--|---|---|----------------|----------|--|--|--|--|--|
| ☐ ARVYS standard protocol. ☐ Customer-supplied protocol. ☐ Existing protocol with an adjustment/optimization. Specify: |   |   |                |          |  |  |  |  |  |
| Novel protocol.  |   |   |                |          |  |  |  |  |  |
|  | Purification method development. Specify: |   |                |          |  |  |  |  |  |
| Assays to be performed at ARVYS  |   |   |                |          |  |  |  |  |  |
| ASSAY  | EXPRESSION                                | PURIFICATION                                | FINAL PRODUCT  | COMMENTS |  |  |  |  |  |
| SDS-PAGE   |   |   |                |          |  |  |  |  |  |
| IEF-PAGE   |   |   |                |          |  |  |  |  |  |
| Dot Blot   |   |   |                |          |  |  |  |  |  |
| Western Blot<br>ELISA  |   |   |                |          |  |  |  |  |  |
|  |   |   |                |          |  |  |  |  |  |
| Protein Assay Absorption at 280nm  |   |   |                |          |  |  |  |  |  |
| Isotyping (strips)   |   |   |                |          |  |  |  |  |  |
| Endotoxin (LAL)  |   |   |                |          |  |  |  |  |  |
| Other  |   |   |                |          |  |  |  |  |  |
| Other  |   |   |                |          |  |  |  |  |  |
| Assays to be performed by the customer. Specify:  FINAL PRODUCT SPECIFICATIONS:  |   |   |                |          |  |  |  |  |  |
| Required amount, mg  |   |   |                |          |  |  |  |  |  |
| Required purity, >%  |   |   |                |          |  |  |  |  |  |
| Preparation  |   | Aqueous Lyophilized                         |                |          |  |  |  |  |  |
| Aliquot size,  ml or [   | □mg                                       |   |                |          |  |  |  |  |  |
| Concentration range, n   | ng/ml                                     |   |                |          |  |  |  |  |  |
| Formulation buffer   |   |   |                |          |  |  |  |  |  |
| Remove specific conta  | minants                                   |   |                |          |  |  |  |  |  |
| Remove endotoxin, <eu mg<="" td=""><td colspan="6"></td></eu>  |   |   |                |          |  |  |  |  |  |
|  |   | Existing protocol: Yes No                   |                |          |  |  |  |  |  |
|  |   | Paste references and/or your own protocols: |                |          |  |  |  |  |  |
|  |   |   |                |          |  |  |  |  |  |
|  |   |   |                |          |  |  |  |  |  |
| Shipping temperature,  | °C  |   |                |          |  |  |  |  |  |
| Other  |   |   |                |          |  |  |  |  |  |
| Antibody characterizat   | ion. Specify:                             |   |                |          |  |  |  |  |  |
|  |   |   |                |          |  |  |  |  |  |
|  | G '.C                                     |   |                |          |  |  |  |  |  |
| Antibody Labeling.   | Specify:                                  |   |                |          |  |  |  |  |  |
|  |   |   |                |          |  |  |  |  |  |
| Antibody conjugation. Specify:   |   |   |                |          |  |  |  |  |  |
| Antibody conjugation. Specify.   |   |   |                |          |  |  |  |  |  |
|  |   |   |                |          |  |  |  |  |  |
|  |   |   |                |          |  |  |  |  |  |
|  | 1447                                      | DIALO DEOVICE                               | D DV THE OHOTO | MED      |  |  |  |  |  |
| MATERIALS PROVIDED BY THE CUSTOMER   |   |   |                |          |  |  |  |  |  |



| ITEM                                 | DESCRIBE AND SPECIFY AMOUNTS |
|--------------------------------------|------------------------------|
| Cell line                            |                              |
| Conditioned media                    |                              |
| Ascites                              |                              |
| ☐ Intermediate purification products |                              |
| Reference sample                     |                              |
| Antigen                              |                              |
| Other                                |                              |
|                                      |                              |
| YOUR COMMENTS/ADDITIONAL INFO:       |                              |
|                                      |                              |
|                                      |                              |
|                                      |                              |
|                                      |                              |
|                                      |                              |
|                                      |                              |
|                                      |                              |
|                                      |                              |
|                                      |                              |
|                                      |                              |
|                                      |                              |
|                                      |                              |
|                                      |                              |
|                                      |                              |
|                                      |                              |
|                                      |                              |